Immuno-oncology
Commentary
Discontinuing immunotherapy: Is the infusion bag half empty or half full?
Clinical trials of immunotherapy or chemoimmunotherapy have generally terminated treatment in nonprogressing patients after 2 years.
Conference Coverage
Acetaminophen linked to diminished response to immunotherapy in cancer
“Commonly used medications may have a larger impact on the efficacy and toxicity of immune checkpoint blockade than historically seen with...
From the Journals
Age, skin cancer risks for ICI-induced bullous pemphigoid identified
“It’s harder to understand why a presumably antibody-mediated side effect would be more likely to have that cross-reactivity where the tumor...
From the Journals
New injectable gel can deliver immune cells directly to cancer tumors
The gel “is a really exciting step forward because it can change the delivery of these cells and expand this kind of treatment to other cancers...
Conference Coverage
CAR-T in children branching out to solid tumors
News from the FDA/CDC
FDA approves new indications for pembrolizumab
From the Journals
Lenvatinib/pembrolizumab has good activity in advanced RCC, other solid tumors
Two-thirds of patients with advanced renal cell carcinoma had a clinical response to the TKI/immune checkpoint inhibitor combination.
Conference Coverage
Dual immunotherapy goes the distance in MSI-H colorectal cancer
SAN FRANCISCO – At a median follow-up of almost 20 months, combination nivolumab and ipilimumab remained highly active as first-line therapy for...
From the Journals
T-VEC plus pembrolizumab yields promising response rate in phase 2 sarcoma study
About one in three patients had a response, translating into the highest objective response rate seen in a study of unselected sarcoma patients...
Video
Experts break down latest CAR T-cell advances in lymphoma
ORLANDO – An expert panel of physicians discusses the latest research on CAR T-cell therapy in lymphoma, presented at the 2019 annual meeting of...
Conference Coverage
CAR T cells produce complete responses in T-cell malignancies
ORLANDO – There were no cases of severe cytokine release syndrome or severe neurotoxicity reported with the anti-CD5 chimeric antigen receptor T...